299 results about "Human lung" patented technology

This relates to a device for treating lung disease, and more particularly, relates to a device for exchanging energy with airway tissue such as that found in the airways of human lungs. The exchange of energy with this airway tissue in the airways reduces the ability of the airways to constrict and/or reduces the resistance within the airway to the flow of air through the airway.

A method for studying scaffold-based tissue engineering approaches in combination with the use of progenitor or stem cells to generate new lung tissue in an in vitro system. The engineered tissue system of this invention is used to monitor lung and immune system exposure of pathogen and/or toxins. The method involves growing engineered lung/immune tissue from progenitor cells in a bioreactor and then exposing the engineered lung/immune tissue to a pathogen and/or toxin. Once exposed, response of the engineered tissue is monitored to determine the effects of exposure to the immune component of the tissue and to lung component of the tissue. This invention also involves development of mixed engineered tissues including a first fully functional engineered tissue such as lung tissue and a second fully functional engineered tissued such as immune tissue from a single animal donor. The mixed systems can include more than two engineered tissues.

The invention discloses a method for culturing normal human lung tissue and a lung cancer tissue organoid in an in-vitro manner. The method includes: acquiring fresh human-derived lung tissue cells, and performing collagen digestion on the fresh human-derived lung tissue cells to obtain single cells; culturing human lung tissue and the lung cancer tissue organoid under in-vitro 3D culture conditions; performing H&E staining to determining the structure and form, and using q-PCR to detect related gene expression; using immunofluorescent staining to authenticate cell sources and detect related protein expression. The invention further discloses a method for building a mouse animal model based on the organoid. The method for culturing the normal human lung tissue and the lung cancer tissue organoid and the method for building the mouse animal model have the advantages that the methods are significant to the building of large-scale and good-consistency human-derived in-situ lung cancer animal models, and a good basis and related application prospect are provided for the fundamental researches of lung cancer.

The present invention comprises imaging and quantitative measurement of lung ventilation, particularly in a human lung. Methods for quantitative imaging of lung ventilation, and the further provided systems and algorithmic tools therefore, comprise three primary components: the combined MRI ventilation/perfusion (V/Q) imaging techniques using hyperpolarized helium-3 (³He) gas (H³He); the three-dimensional quantitative imaging of absolute lung perfusion (Q) and collection of local magnetic resonance image data therefrom to produce an absolute lung perfusion image data; and the algorithmic co-registration of the two image data sets, (HP-³He MRI image of V/Q and MR imaging of quantitative perfusion (Q) in the lung). From the data acquired in the combined data sets and their spatial co-registration, absolute ventilation (V) is computed.

The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549 and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.

The invention discloses a multifunctional fusion polypeptide and a preparation method and application thereof, and belongs to the field of biological pharmacy. The fusion polypeptide has the structural domains of Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu, Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, Arg-Gly-Asp and Gly-Gly-Gly-Gly; the fusion polypeptide can treat human lung fibrosis, pathological changes of lung tissue, lung cancers and other tumors, and in a lung fibrosis cell model, the fusion polypeptide can significantly reduce the hydroxyproline content in model group cells and inhibit the process of lung fibrosis. It is shown through MTT tests that the fusion polypeptide can inhibit proliferation of multiple kinds of anthropogenic tumor cells; the fusion polypeptide is prepared through an artificial synthesizing method, the preparation method is simple, and a good application prospect is achieved.

A battery filling system for use in efficiently adding water to, for example, those lead-acid batteries which are located in inconvenient or hard-to-reach places. The battery filling system includes a first flexible tube for use in transferring distilled water from the interior of a water-filled vessel to the hard-to-reach cell of a lead-acid battery. A second flexible tube transfers pressurized air from an external pressurized air source (typically human lungs) to the interior of the vessel in a quantity sufficient to cause the water to advance into and fill the first tube. A cap is used to snugly attach both tubes to the vessel. A means is also provided to minimize loss of air pressure from the vessel.

The invention provides an estimation of key flow-independent parameters characteristic of NO exchange in the lungs, namely: 1) the steady state alveolar concentration, C_alv,ss; 2) the maximum flux of NO from the airways, J_NO,max; and 3) the diffusing capacity of NO in the airways, D_NO,air. The parameters were estimated from a single exhalation maneuver comprised of a pre-expiratory breathhold, followed by an exhalation in which the flow rate progressively decreased. The mean values for J_NO,max, D_NO,air, and C_alv,ss do not depend on breathhold time for breathhold times greater than approximately 10 seconds. A priori estimates of the parameter confidence intervals demonstrates that a breathhold no longer than 20 seconds may be adequate, and that J_NO,max be can estimated with the smallest uncertainty, and D_NO,air the largest.

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.

The invention discloses a pro-drug as shown in general formula (I), which is formed by coupling camptothecin or a derivative of the camptothecin with non-linear configuration glycol polyethylene, wherein, the definition for varied groups is available in the specification. A physiological disposition research on nude mice discloses that: the pro-drug has a time-delay plasma concentration - time curve, and the plasma concentration can still be maintained at over 100ng/ml 72 hours after intravenous medication. Evaluation on physiological drug effect shows that the pro-drug has strong growth inhibiting effect against the LOVO HCT116 cell line transplantable tumor inoculated into the nude mice and also has obvious growth inhibitory activity against human lung carcinoma H460 cell line transportable tumor inoculated into the nude mice. The inhibition of the pro-drug is better than that of Irinotecan, a positive control drug and has no obvious systemic toxicity.

Embodiments of the invention relate to human stem cells and their therapeutic use in the treatment and/or prevention of lung diseases. Provided herein are compositions comprising c-kit positive human lung stem cells and methods of preparing and using c-kit positive human lung stem cells for the treatment and/or prevention of lung diseases.

The invention provides a compound having anticancer activity, which is obtained by cooperation of Norabieta cantharidin and platinum (IV) and modification of a piperazine derivative. The compound is characterized in that a Norabieta cantharidin piperazine derivative ligand is introduced, thereby cytotoxicity of a platinum (IV) compound is reduced, and high antineoplastic activity is provided. The result of the cytotoxicity experiments shows that the provided platinum (IV) compound has less destruction to normal mice fibroblast L929, but has good killing effect to cancer cells such as human breast cancer MCF-7 cell, human cervical carcinoma HeLa cell and human lung adenocarcinoma A549 cell, so that the compound having anticancer activity is capable of reducing the system toxicity and having equal anticancer activity with cisplatin. The compound having anticancer activity has good killing effect by aiming at cisplatin resistance human lung adenocarcinoma A549/DDP cell. Therefore, the toxicity is reduced, the cisplatin resistance can be reversed, and anticancer effect of the platinum medicines can be increased.

The invention discloses N'-arylmethylene-2-(4-oxothiophene[2,3-d]pyrimidin-3-yl)acetyl hydrazone compounds, and a preparation method and application thereof. The structural general formula of the compounds is shown as a formula (I). Experimental results indicate that the compounds can induce cells to which Caspase-3 in human cervical carcinoma cells, human lung carcinoma cells and human breast carcinoma cells is dependent to die so as to inhibit the propagation of the carcinoma cells, also have low toxicity on normal cells, and can be used for preparing antitumor medicines for treating cervical carcinoma, lung cancer or breast cancer.

The invention relates to the technical field of medical appliances, discloses a device for implementing lung volume reduction surgery, and particularly discloses an anatomical lung volume reduction elastic bracket, which can be implanted into a human lung. The anatomical lung volume reduction elastic bracket can be implanted into the tail end of the lung bronchus of a patient in a minimally invasive manner in order to eliminate the influence of tissues with severe emphysema lesion on lung function and achieve the effect of treating chronic diffuse emphysema. The anatomical lung volume reduction elastic bracket comprises a bracket body and spherical structures which are fixed to the two ends of the bracket respectively. The bracket is at a linear state at the normal temperature, and is in a U-shaped state after being released in vivo.

The invention belongs to the field of study on respiratory physiology and discloses a device and control method for simulating the spontaneous respiratory movement of the human lung. The device comprises a simulated lung cavity, springs, a pull rope, a flow sensor, a touch display screen, a motor driver, a direct-current servo motor and a control circuit. The respiratory physiological parameters including the inspiration and expiration ratio, the respiratory rate, the tidal volume and the vital capacity are input through the touch display screen; the flow of air passing by the air change port of the simulated lung cavity is detected by the flow sensor; a motor control signal is triggered by a microcontroller according to the set respiratory parameters and the detected flow signal; further the reeling and the unreeling of the pull rope are controlled by the motor; and finally the respiratory movement of the simulated lung cavity is controlled. The device disclosed by the invention is more in line with the respiratory physiology of the human lung and has extremely high application values in the aspects of scientific research, teaching and respiratory-related product testing.

A method of identifying proteins present in human serum which are differentially expressed between normal individuals and patients known to have non-small cell lung cancers and asthma, as diagnosed by a physician. Human serum specimens from each population are digested with trypsin or any other suitable endoproteinase and analyzed using a liquid chromatography electrospray ionization mass spectrometer. Mass spectral data from each population is compared to determine proteins with expression intensities which are significantly differentially expressed between the normal, asthma, and lung cancer populations. Eleven proteins are found to have expression intensities which are significantly differentially expressed between the populations. Finally, the identities of the eleven proteins are obtained by comparing the mass spectral data with known databases having libraries of mass spectral data of known proteins.

The invention discloses a tracking device for simulating the motion of a human lung tumor. The tracking device comprises a simulated lung model, a simulated breathing device which is connected with the simulated lung model and makes the simulated lung model expand and contract, a sensor which is arranged on the simulated lung model and represents a tumor, and a data processing device which is connected with the sensor. The sensor collects motion data thereof, and sends the data to the data processing device. The simulated breathing device reproduces the real breath of a human body. The sensor representing a tumor collects motion data thereof and sends the data to the data processing device, and then, motion law data of a lung tumor can be obtained. Therefore, the accuracy of radiotherapy can be improved.

The invention discloses a DQA-PEG 2000-DSPE (Dequalinium Chloride-Polyethylene Glycol-Distearoyl Phosphatidyl Ethanolamine) conjugated compound and resveratrol liposome modified thereby. The structural formula of the compound is shown by a formula I. In terms of composition, the resveratrol liposome comprises resveratrol and a fat material, wherein the mass ratio of the resveratrol to the fat material is (1:20)-(1:40); and the fat material consists of egg yolk lecithin, cholesterol and the compound shown by the formula I in the molar ratio of (63-67):(18-22):(2-4.35) in sequence. Pharmacodynamic tests prove that mitochondrial targeted resveratrol liposome has an extremely strong cell toxic effect in in-vitro cell experiments of human lung adenocarcinoma A549 cells and drug-resistant A549/cDDP cells thereof, a tumor sphere model and an in-vivo transplantation tumor model and can penetrate through the core of the tumor sphere. The anti-tumor effect of vinorelbine liposome on the drug-resistant A549/cDDP cells can be obviously improved by combining the resveratrol liposome with the vinorelbine liposome for use (formula I).